Disc Medicine (IRON) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IRON Disc Medicine

Watchlist

44.820
-0.780-1.71%

Close Oct 31 16:00 ET

44.820
0.0000.00%

Post 16:03 ET

1.33BMarket Cap-12381P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scotiabank Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $62
Moomoo NewsOct 28 08:35 ET · Ratings
Disc Medicine Analyst Ratings
BenzingaOct 28 08:20 ET · Ratings
Disc Medicine (IRON) Receives a Buy From Scotiabank
TipRanksOct 28 07:36 ET · Ratings
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
Moomoo NewsOct 28 06:31 ET · Ratings
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
Moomoo NewsOct 25 14:31 ET · Ratings
Disc Medicine's DISC-0974 Shows Promising Potential for Anemia Treatment, Earning Buy Rating
TipRanksOct 25 14:15 ET · Ratings

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

7122413

Apr 1 12:52

$Disc Medicine (IRON.US)$ easy money

Invest with Sarge

Apr 1 11:15

Not Ironman ...

Disc Medicine $Disc Medicine (IRON.US)$ down 55% on Monday.

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Analysts Notebook

Dec 27, 2023 04:18

Columns Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

IRON Disc Medicine

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target